Antimicrobial effect of Morita-Baylis-Hillman adducts against oral pathogens and cellular viability in human leukocytes / Efeito antimicrobiano de adutos de Morita-Baylis-Hillman contra patógenos orais e viabilidade celular em leucócitos de humanos

• Autor(a) principal: Maciel, Panmella Pereira
• Data de Publicação: 2021
• Outros Autores: de Lima, Jefferson Muniz, Maciel, Patrícia Pereira, Maior, Laura de Fátima Souto, Bonan, Roberta Ferreti, Sousa, Suervy Canuto de Oliveira, Vasconcellos, Mário Luiz Araújo de Almeida, Castellano, Lúcio Roberto Cançado, Bonan, Paulo Rogério Ferreti
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Veras
• DOI: 10.34117/bjdv7n8-339
• Texto Completo: https://ojs.brazilianjournals.com.br/ojs/index.php/BRJD/article/view/34431
• topic: Microbiology; Organic Chemicals; Cytotoxicity Tests; Immunologic; Leukocytes.

The aim of this work was to evaluate Morita-Baylis-Hillman adduct (MBHA) antimicrobial effect against oral pathogens and related cell viability in human leukocytes. Minimum inhibitory concentration (MIC) was determined using microdilution method. Cell viability was assessed in human peripheral blood mononuclear cells (PBMCs) using the resazurin assay. For S. aureus (ATCC 15656) and S. mutans (UA 159) MIC values of 2,000 ?g/mL were reported for the A1 Morita-Baylis-Hillman adducts. The MICs of the A2 and A3 adducts were not found for the bacterial strains. MIC values for the A1 adduct was 125 ?g/mL, A2 1,000 ?g/mL and A3 to 15.6?g/mL against the C. albicans strain (ATCC 11006). PBMCs showed cell viability greater than 50 % when in contact with concentrations 10x higher than MIC of MBHA. It is concluded that MBHA A1, A2 and A3 present potential antimicrobial effects against C. albicans without presenting substantial cytotoxic effects in human cells, highlighting adduct A3 for future therapeutic applications.